IF IT LOOKS LIKE A DUCK AND QUACKS LIKE A DUCK IT MUST BE A DUCK! THIS DUCK’S NAME IS PROLECTIN AND IT LOOKS LIKE A CURE FOR COVID – 19.
I am not a medical doctor or scientist but I do know a “duck” when I see one and here is what ProLectin looks like: •
The developer of ProLectin is BioXyTran Inc. (BIXT on OTC MARKETS), a clinical stage biotech company, led by CEO Dr. David Platt who has had over 30 years’ experience with remarkable success developing molecules in this same field of research. Dr. Platt says that his approach to drug development is called ‘precision medicine.’ What makes the ProLectin molecule unique is that it is designed to stay in the blood and attach to the COVID-19 protein spikes. When ProLectin’ s galectin inhibitor binds to the virus spike it effectively prevents it from entering healthy cells and tags it for elimination through the liver.
To date, phase 1 and 2 human trials and randomized clinical testing of ProLectin have shown a benign safety profile and lack of toxic side effects. Phase 3 human testing is underway.
Following are the forms of ProLectin:
Dr. Platt has written that ProLectin-M is not just about COVID-19. It can also work against several similar viruses like Adenovirus (common cold) and Influenza which both contain the same target receptor.
The facts are that for too many reasons people are still getting infected with COVID-19 worldwide in record numbers! More unwelcome news is the public health experts predict that COVID-19 infections are going to continue for some time to come. There is however some good late breaking news that the medical science community is directing new emphasis and resources on therapeutic treatments for COVID-19.
It seems simple to me, that heaven forbid, however one gets infected, there needs to be safe effective ways to treat this insidious disease that will keep us out of the hospital and alive. From what I can tell, so far there are no CDC/ NIH / FDA approved COVID-19 therapeutic treatments that are is anywhere near 100% effective. The best ones that have been approved have an effective range from 25% to 80% ! Further, they are all complicated and very expensive to manufacture compared to ProLectin according to Dr. Platt.
In closing, BEWARE of the “Snake Oil” salespeople promoting unapproved and bogus treatments such as: Chloroquine, Ivermectin, injecting bleach, swallowing or bathing in disinfectants or rubbing alcohols!
As the saying goes, “if it sounds too good to be true, and there is no credible scientific evidence, it most likely is too good to be true !
For the record, I am not an employee or paid promoter of BioXyTran ! However, I am rooting for ProLectin-M to be the “Game Changer” we have been waiting for!
Galectin approach to lower covid transmission
ProLectin-M (PL-M), a Gal-3 antagonist, has been shownto have anti-SARS-CoV-2 activity.Conclusion PL-M is safe and effective for clinical use in reducing viral load and promoting rapid viral clearance in COVID-19 patients by inhibiting SARS-CoV-2 entry into cells through inhibition of Gal-3.
Bioxytran is a clinical stage pharmaceutical company developing platform technologies in the fields of Glycovirology, Hypoxia and Degenerative Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design.
Bioxytran uses Galectin inhibitors to combat the virus, SARS-CoV-2. The technology is built on the lifetime work of company’s founder, David Platt, PhD. Dr. Platt expressed, and named, the Human Galectin-3 protein coded by a single gene, LGALS3, located on chromosome 14. Galectin inhibitors block the binding of galectins to carbohydrate structures, present in numerous diseases, reducing their capability to replicate. Dr. Platt has over the years used this knowledge to create a significant number of sustainable therapeutic solutions.
BioxyTran Inc is also developing treatments for hypoxic conditions, necrosis, and degenerative diseases that utilize the carrying of oxygen to affected areas for stroke, wound, and brain damage treatment. The platform’s initial IP position includes an issued patent and provisional patents developed and assigned by the founder of the company, David Platt, PhD.
Note: This information was taken verbatim from the BioXyTran web site.